New Delhi, May 30 (IANS) In a significant boost to India’s medtech innovation landscape, the Technology Development Board (TDB), under the Union Department of Science and Technology (DST), on Friday announced financial support to the development of India’s first indigenous thrombectomy device for stroke care.
The board sanctioned assistance to Mysuru-based S3V Vascular Technologies’ pioneering neuro-intervention integrated manufacturing plant for the treatment of stroke, which sees nearly 1.5 million cases every year in the country.
The project envisions the establishment of a state-of-the-art upstream integrated manufacturing facility at the Medical Devices Park, Oragadam in Chennai’s Sriperumbudur.
The plant will develop and manufacture advanced mechanical thrombectomy kits — a life-saving intervention for patients suffering from acute ischemic stroke due to large vessel occlusion.
Compared to conventional thrombolysis, thrombectomy offers significantly improved outcomes, reducing the risk of long-term paralysis and disability.
“The TDB is proud to support S3V’s vision of building India’s first comprehensive neuro-intervention manufacturing ecosystem. This project reflects our continued commitment to making India a global hub for affordable, high-end medical technology — especially in areas of critical public health needs like stroke care,” TDB Secretary Rajesh Kumar Pathak said.
“The company’s focus on integrating these devices into Ayushman Bharat further aligns with the national goal of inclusive healthcare access,” he added.
The initiative will help replace expensive imported devices with high-quality, locally manufactured alternatives, enhancing both the affordability and accessibility of stroke care in India.
“Our integrated manufacturing facility will not only reduce dependency on imports of the finished medical devices used in Mechanical Thrombectomy but also reduces India’s dependency on import of the raw materials used in manufacturing of these critical complex lifesaving medical devices,” S3V Vascular Technologies Managing Director, Dr N.G. Vijaya Gopal, said, while lauding the government for its support.
Gopal said the company has already initiated the CE and the US FDA approval process for the devices to expand access to cutting-edge stroke care solutions across India, Asia, Latin America, Europe, and the US.
–IANS
rvt/vd
Disclaimer
The information contained in this website is for general information purposes only. The information is provided by BhaskarLive.in and while we endeavour to keep the information up to date and correct, we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, reliability, suitability or availability with respect to the website or the information, products, services, or related graphics contained on the website for any purpose. Any reliance you place on such information is therefore strictly at your own risk.
In no event will we be liable for any loss or damage including without limitation, indirect or consequential loss or damage, or any loss or damage whatsoever arising from loss of data or profits arising out of, or in connection with, the use of this website.
Through this website you are able to link to other websites which are not under the control of BhaskarLive.in We have no control over the nature, content and availability of those sites. The inclusion of any links does not necessarily imply a recommendation or endorse the views expressed within them.
Every effort is made to keep the website up and running smoothly. However, BhaskarLive.in takes no responsibility for, and will not be liable for, the website being temporarily unavailable due to technical issues beyond our control.
For any legal details or query please visit original source link given with news or click on Go to Source.
Our translation service aims to offer the most accurate translation possible and we rarely experience any issues with news post. However, as the translation is carried out by third part tool there is a possibility for error to cause the occasional inaccuracy. We therefore require you to accept this disclaimer before confirming any translation news with us.
If you are not willing to accept this disclaimer then we recommend reading news post in its original language.
